Table 2.
Delta changes in parameters of blood pressure and diabetes control.
| BP (mmHg) at initiation of SGLT2i treatment | |||
|---|---|---|---|
| Well-controlled group (n = 327) | Poorly controlled group (n = 413) | p value | |
| Δlogarithmic value of ACR | −0.13 ± 1.05 | −0.24 ± 0.97 | n.s. |
| ΔeGFR (ml/min/1.73 m2) | −1.8 ± 10.9 | −4.0 ± 11.2 | 0.007 |
| ΔCCR (ml/min) | −6.0 ± 14.7 | −9.0 ± 17.7 | 0.016 |
| ΔHbA1c (mmol/mol) (%) | −6.2 ± 12.6 | −8.5 ± 14.7 | 0.023 |
| ΔBW (kg) | −2.4 ± 3.6 | −2.7 ± 4.4 | n.s. |
| ΔSBP/ΔDBP at office (mmHg) | 2.6 ± 15.7/3.5 ± 10.0 | −12.8 ± 18.3/−5.6 ± 10.2 | <0.001/<0.001 |
| ΔMAP at office (mmHg) | 3.2 ± 10.3 | −8.0 ± 11.2 | <0.001 |
|
| |||
| MAP (mmHg) at the time of the survey | |||
| <102 (n = 537) | ≥102 (n = 203) | p value | |
| Δlogarithmic value of ACR | −0.25 ± 1.02 | −0.03 ± 0.97 | <0.001 |
| ΔeGFR (ml/min/1.73 m2) | −3.2 ± 11.0 | −2.7 ± 11.4 | n.s. |
| ΔCCR (ml/min) | −8.3 ± 15.4 | −5.9 ± 18.4 | n.s. |
| ΔHbA1c (mmol/mol) (%) | −7.4 ± 13.8 | −7.8 ± 14.0 | n.s. |
| ΔBW (kg) | −2.8 ± 3.7 | −1.9 ± 4.8 | 0.004 |
| ΔSBP/ΔDBP at office (mmHg) | −8.7 ± 17.7/−3.2 ± 10.5 | 1.2 ± 19.9/2.8 ± 11.4 | <0.001/<0.001 |
| ΔMAP at office (mmHg) | −5.0 ± 11.4 | 2.3 ± 12.6 | <0.001 |
Abbreviations: ACR: urinary albumin-creatinine ratio; BW: body weight; CCR: creatinine clearance, calculated by the Cockcroft-Gault formula; DBP: diastolic blood pressure; Δ: change in; eGFR: estimated glomerular filtration rate; HbA1c: hemoglobin A1c; MAP: mean arterial pressure; n.s.: not significant; SGLT2i: sodium-glucose cotransporter 2 inhibitors; SBP: systolic blood pressure.